"In this issue of Nature Medicine, Yap et al.4 report on a phase I trial evaluating a potent mitochondrial inhibitor5 (IACS-010759) in individuals with acute myeloid leukemia and solid tumors. Unfortunately, promising preclinical findings did not translate into the clinic as intolerable neurotoxicity precluded adequate dosing, prompting the question — what lessons can be learned from this disappointing outcome?"
@cyrilpedia Relevant reporting in the field of #translationalmedicine because not every "negative" #Trial is also uninformative...it is quite the opposite, every patient counts.
@halama_immuno Absolutely! And the data from trials with negative results should be made available
I would very much like to know what happened in the Alda-1 trial.
https://www.deltanutra.com/blogs/news/an-aldh2-deficiency-drug-mystery-aldea-pharmaceutical-s-alda-1
@cyrilpedia @halama_immuno
Data that is negative should always be reported yet it's highly frowned upon in literature